Previous 10 | Next 10 |
Shares of Aeglea BioTherapeutics (NASDAQ: AGLE) , a clinical-stage biopharmaceutical company , are falling today in response to mixed clinical-trial data. Investors nervous about the future of the company's lead candidate pushed the stock 36.6% lower as of 11:53 a.m. ET on Monda...
Gainers: Del Taco Restaurants (NASDAQ:TACO) +66%. Insignia Systems (NASDAQ:ISIG) +64%. Adicet Bio (NASDAQ:ACET) +37%. Cloopen Group (NYSE:RAAS) +24%. eFFECTOR Therapeutics (NASDAQ:EFTR) +20%. Recruiter (NASDAQ:RCRT) +21%. Edgewise Therapeutics (NASDAQ:EWTX) +21%. Liberty TripAdvisor (NASDAQ:L...
Alset EHome International (NASDAQ:AEI) -43% prices $30M stock offering TuanChe (NASDAQ:TC) -18%. Lucid Group (NASDAQ:LCID) -15%. Hut 8 Mining (NASDAQ:HUT) -15%. Bitfarms (NASDAQ:BITF) -15%. Aeglea BioTherapeutics (NASDAQ:AGLE) -14% says pivotal trial for pegzilarginase in ...
Aeglea BioTherapeutics (NASDAQ:AGLE) announced that its Phase 3 pivotal trial for pegzilarginase in Arginase 1 Deficiency met the primary endpoint. However, a key measure designed to assess the patient's mobility have not achieved statistical significance. Aeglea (AGLE) have lost ~18.0%&...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back, trader! We’re starting off the week with a look at the biggest pre-market stock movers for Monday! Source: Eric Urquhart/Shutterstock.com News moving stocks this morning include falling crypto p...
Aeglea BioTherapeutics Announces Achievement of Primary Endpoint in Phase 3 Study of Pegzilarginase in Patients with Arginase 1 Deficiency 80% plasma arginine reduction (primary endpoint; p < 0.0001) accompanied by a positive trend in GMFM-E, a key clinical assessment of pati...
Aeglea BioTherapeutics to Host Conference Call to Report Phase 3 Topline Results of Pegzilarginase in Patients with Arginase 1 Deficiency Event Scheduled for 8:00 a.m. ET Monday, December 6, 2021 PR Newswire AUSTIN, Texas , Dec. 5, 2021 /PRNewswire/ -- Aeglea...
Aeglea BioTherapeutics Appoints Hunter C. Smith to Board of Directors PR Newswire AUSTIN, Texas , Nov. 16, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therape...
Aeglea BioTherapeutics (NASDAQ:AGLE): Q3 GAAP EPS of -$0.31 misses by $0.01. Revenue of $1.39M Press Release For further details see: Aeglea BioTherapeutics EPS misses by $0.01
Aeglea BioTherapeutics Reports Third Quarter 2021 Financial Results and Corporate Highlights PEACE baseline data at upcoming medical meeting underscore disease severity and significant limitations of current standard of care in controlling plasma arginine levels Topline safe...
News, Short Squeeze, Breakout and More Instantly...
Aeglea BioTherapeutics Inc. Company Name:
AGLE Stock Symbol:
NASDAQ Market:
Aeglea BioTherapeutics Inc. Website:
Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire Company will begin trading on Nasdaq under trading sy...
2023-11-20 05:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update PR Newswire Continued progress across the Company's potentially best-in-class inflammatory bowel disease (IBD) portfolio SPY001, a half-life extended anti-α4β...